Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • daclatasvir

    - PMLiVE

    Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

    An estimated 1.2 million people in the US are currently living with the virus

    - PMLiVE

    Gilead Sciences’ twice-yearly HIV PrEP drug Yeztugo granted FDA approval

    More than 100 people in the US were diagnosed with HIV every day in 2023

    - PMLiVE

    Cultivating Interest in Infectious Disease Education at ID Week 2024

    IDWeek starts tomorrow, October 16, and Medscape is bringing outcomes and education! We are excited to announce Medscape is presenting six posters that highlight the significant impact of our educational...

    Medscape Education

    - PMLiVE

    Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

    “I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

    Medscape Education

    - PMLiVE

    Gilead and NHS England extend collaboration to eliminate hepatitis C by 2025

    The blood-borne disease is estimated to affect around 62,600 people in England

    - PMLiVE

    Bristol Myers Squibb’s subcutaneous Opdivo shows promise in kidney cancer

    More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

    - PMLiVE

    BMS announces CHMP recommendation for multiple myeloma therapy Abecma

    More than 50,000 cases of the blood cancer are diagnosed in Europe every year

    - PMLiVE

    BMS, Exelixis and Ipsen announce positive four-year results for kidney cancer regimen

    More than 430,000 new cases of renal cell carcinoma are diagnosed globally every year

    - PMLiVE

    BMS presents promising late-stage results for Opdivo plus Yervoy in colorectal cancer

    More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020

    - PMLiVE

    Bristol Myers Squibb’s Opdualag recommended by NICE for advanced melanoma

    More than 16,700 new cases of melanoma are diagnosed in the UK every year

    - PMLiVE

    Bristol Myers Squibb to acquire radiopharmaceutical specialist RayzeBio for $4.1bn

    The merger includes a candidate in phase 3 development for gastroenteropancreatic neuroendocrine tumours

    - PMLiVE

    Bristol Myers Squibb’s Opdualag approved by MHRA for advanced melanoma

    Approximately 17,000 cases of melanoma are diagnosed in the UK every year

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links